Investment Pitches

Pitch Summary:
Xponential Fitness has emerged from a challenging period marked by an SEC investigation, which concluded without action against the company, lifting a significant cloud of uncertainty. The company is now refocusing on its core business fundamentals, with ambitious growth targets including a 10% annual increase in net new studios and high-margin franchise royalties. Despite recent slowdowns in revenue growth and studio openings, the company's strong pipeline of committed studio openings and historical growth trajectory suggest potential for significant upside. The current valuation appears to underestimate the company's growth prospects, providing a compelling investment opportunity.

BSD Analysis:
Xponential Fitness's business model, centered on high-margin franchise royalties, positions it well for profitability as it expands its studio footprint. The company's historical revenue growth, with a CAGR of 30.8% since 2018, underscores its capability to scale effectively. However, the recent increase in studio closures and slower revenue growth highlight challenges in franchisee financial health and market saturation. The company's DCF valuation suggests a fair value of $14.76, indicating a 46% upside from current levels, even with conservative growth assumptions. The cost of capital, calculated at 11.00% using a WACC approach, reflects the risks associated with the company's debt levels and market volatility. Overall, while the investment carries risks, particularly in achieving long-term growth targets, the potential rewards justify a bullish stance.

Pitch Summary:
AbbVie has been a strong performer, driven by its immunology division and successful drugs like Skyrizi and Rinvoq. However, recent M&A activities, including the acquisitions of Cerevel Therapeutics and Immunogen, have led to significant write-downs and increased debt. While the company continues to generate substantial revenues, its reliance on a few key products and mixed results from recent acquisitions suggest a cautious outlook. The stock is currently a 'Hold' as AbbVie navigates these challenges and seeks to leverage its recent acquisitions for future growth.

BSD Analysis:
AbbVie's recent acquisitions have not yet delivered the expected returns, leading to substantial write-downs, particularly with Cerevel's emraclidine failing in Phase 2 trials. The company's debt level is concerning, with $64.7 billion in long-term debt against $5.2 billion in cash. Despite these challenges, AbbVie's core immunology division remains robust, contributing significantly to its revenue. The company's strategy to diversify through smaller, potentially high-impact acquisitions like Gubra and Capstan could pay off if these early-stage assets succeed. The obesity market, targeted through the Gubra acquisition, presents a significant growth opportunity, potentially mirroring the success of Eli Lilly's tirzepatide. AbbVie's ability to manage its debt and improve its R&D outcomes will be crucial for sustaining long-term growth and maintaining investor confidence.

Pitch Summary:
KKR & Co is positioned to capitalize on its strong fundraising capabilities and diversified investment strategies, despite recent earnings volatility. The firm's access to trending markets like private credit and infrastructure, combined with its robust asset management and strategic partnerships, supports a positive long-term growth outlook. The stock appears slightly undervalued based on a DCF valuation, suggesting potential upside for long-term investors.

BSD Analysis:
KKR's financial performance in Q1 2025 was impacted by a normalization of insurance revenues, yet its fee-related earnings and investment income showed resilience, indicating sustainable growth. The firm's AUM increased by 15% year-over-year, reflecting its strong market position. KKR's forward P/E ratio of 25.38x, while high, is competitive within the industry, especially against peers like Blackstone and Ares Management. The firm's strategic acquisitions and partnerships, such as those with Catalio Capital Management and WEAVE LIVING, enhance its market reach and expertise in key sectors. Despite potential risks from economic downturns and regulatory changes, KKR's global presence and liquidity provide a buffer against market volatility. The firm's ability to raise significant capital further strengthens its competitive edge, positioning it well for future growth in the expanding private credit and infrastructure markets.

Pitch Summary:
AutoZone has demonstrated exceptional long-term performance with a significant historical return on investment. However, recent earnings have missed expectations, and the company faces challenges with declining margins and a high valuation. Despite strong buyback programs and growth initiatives, the current price does not offer a compelling entry point due to uncertainties in future earnings growth.

BSD Analysis:
AutoZone's historical success is rooted in its ability to expand margins and leverage operating efficiencies, evidenced by its operating margin increase from 9.69% in 1991 to 20.5% today. However, recent trends show a decline in net income margins, raising questions about whether this is a temporary dip or a longer-term issue. The company's aggressive share buyback strategy has been a key driver of EPS growth, reducing shares outstanding by nearly 90% since 1998. Despite these strengths, AutoZone's current P/E ratio of 25x suggests a premium valuation, which may not be justified given the recent earnings trajectory and market conditions. The company's growth strategy focuses on expanding its retail and commercial presence, both domestically and internationally, with a particular emphasis on underpenetrated markets. While these initiatives hold promise, they also carry execution risks, particularly in international markets where demand is uncertain. For investors, the key will be monitoring the effectiveness of these growth strategies and waiting for a more attractive valuation that offers a better risk-reward profile.

Pitch Summary:
INmune Bio's XPro, a selective TNF inhibitor, shows potential as a treatment for Alzheimer's disease, particularly in patients with confirmed neuroinflammation. Despite missing the primary endpoint in the Phase II MINDFuL trial, the drug demonstrated promising results in a subgroup of amyloid-positive patients with multiple inflammatory biomarkers. XPro's safety profile, without significant immunosuppression, positions it as a viable candidate in the Alzheimer's market, which is projected to grow significantly. The company's upcoming catalysts, including potential regulatory advancements and pipeline developments, could drive substantial upside for the stock.

BSD Analysis:
XPro's mechanism of selectively inhibiting soluble TNF while preserving immune function differentiates it from existing TNF inhibitors, potentially reducing neuroinflammation without the adverse effects seen in other treatments. The Alzheimer's market is poised for growth, with current therapies like Eisai and Biogen's Leqembi priced at $26.5K annually, suggesting a lucrative opportunity for XPro if approved. INmune Bio's market cap of $50M-$60M contrasts sharply with the potential $10B-$12.5B market cap contribution from XPro, assuming a conservative 5% market penetration and industry-standard price-to-sales multiples. However, the company faces financial challenges, with a limited cash runway and the need for additional funding to advance late-stage trials. Strategic partnerships or licensing deals could alleviate financial pressures and support further development. Investors should monitor upcoming data presentations and regulatory interactions, which could significantly impact the stock's trajectory.

Pitch Summary:
4imprint Group Plc is strategically positioned in the marketing services industry, leveraging a direct marketing model to deliver promotional products. The company is expanding its digital infrastructure and product range to include eco-friendly options, aligning with consumer trends. Despite strong historical performance, concerns about tariff impacts and economic sensitivity warrant a cautious approach.

BSD Analysis:
4imprint's focus on enhancing its e-commerce platform and expanding its product offerings to include sustainable options reflects a strategic alignment with current market trends. The company's robust online presence and efficient customer service model support its competitive advantage. However, its reliance on discretionary marketing budgets makes it susceptible to economic downturns, which could impact revenue stability. The potential risks associated with US tariffs on Asian imports, a significant part of its supply chain, could affect profitability unless mitigated through diversification. Despite these challenges, the company's established brand and scalable model offer a solid foundation for growth, provided it manages expansion risks effectively. The recent sell-off due to tariff concerns might present a buying opportunity, but investors should weigh this against the company's exposure to macroeconomic volatility.

Pitch Summary:
Illumin, formerly AcuityAds, is showing signs of recovery after a challenging period in the adtech industry. The company has returned to topline growth and operating leverage, with insiders actively buying shares. Illumin's focus on journey advertising differentiates it from competitors by offering brands transparency and control over consumer decision flows. Despite past execution issues and macroeconomic headwinds, Illumin is now experiencing accelerated growth and profitability. The company has a strong cash position, with over half its market cap in net cash, and is guiding towards sustained growth with expanding margins.

BSD Analysis:
Illumin's strategic shift towards a more efficient sales structure in the U.S. and cost-cutting measures have contributed to its recent positive performance. The adtech industry remains challenging, with pressures from large clients reducing spending and gross margin shifts. However, Illumin's ability to attract new clients and increase spending per client indicates potential for growth. The company's insider buying and 10% buyback signal confidence in its future prospects. While the adtech space is competitive and volatile, Illumin's improved execution and low valuation make it an intriguing small-cap investment opportunity.

Pitch Summary:
On June 16th, Frank Value Fund holding Cantaloupe Inc announced an all-cash transaction to go private at $11.20 per share. This offer is 85% higher than the fund’s initial purchase just nine months ago. Cantaloupe emphasizes the repeatable niche Frank Value Fund enjoys as fewer fundamental analysts are researching s/mid cap companies. Ultimately, when a buyer of the entire company arrives, takeover value will be significantly higher than the public trading price. As with the IPPs, we added significantly to our Cantaloupe position during the tariff tantrum. Quantitative data from our research process allows us to make decisive, opportunistic decisions when volatility and uncertainty are high. We certainly did not expect risk appetite to ravenously return in the past few months, showing why it is important to focus on individual opportunities rather than trying to read the macro tea leaves.

BSD Analysis:
Cantaloupe’s take-private premium underscores the value embedded in its payments and telemetry platform as scale expands across unattended retail. The business has strong recurring revenue characteristics, attractive unit economics, and meaningful operating leverage as customers digitize legacy vending workflows. Management’s execution and the board’s willingness to pursue a sale highlight the disconnect between private-market and public-market valuations. While the go-private deal crystallizes upside, it also validates the fund’s approach of exploiting inefficiencies in under-researched small/mid-cap niches. Key risks would have included competitive pressure and integration complexity, but the all-cash bid removes fundamental uncertainty for shareholders.

Pitch Summary:
It was the right decision to purchase more NRG during the AI factor freakout earlier this year and to also add Vistra to our portfolio amidst the tariff tantrum. Our valuation targets on NRG and Vistra are still materially higher here as most participants (indexers) are apathetic to the fundamentals, which continue to surprise on the upside. NRG and Vistra are far smaller components of the S&P 500 than their fundamentals merit, and these companies will add additional value to shareholders by repurchasing stock at discounted valuations or executing deals like the LS Power acquisition.

BSD Analysis:
Vistra stands to benefit from the same secular tailwinds lifting independent power producers—surging data center electricity demand, tightening reserve margins, and rising capacity prices. The company’s diversified generation fleet and expanding battery storage footprint position it well for the evolving grid. Strong free cash flow supports aggressive buybacks, and current valuation remains below intrinsic value implied by forward power market fundamentals. Index under-representation adds a structural technical tailwind as fundamentals strengthen. Key risks include commodity volatility and regulatory shifts, but Vistra’s asset mix and capital strategy appear well aligned with multi-year demand growth.

Pitch Summary:
The Fund’s #1 holding, NRG Energy, announced a transformative acquisition in Q2, adding generation assets in the Northeast US and Texas. The selling entity, LS Power, elected to take $2.8 billion of the consideration in NRG stock, making LS Power owners of 11% of NRG while committing to a 6-month lockup where LS Power will not sell a share. Clearly, LS Power sees the same positive dynamics in US electricity demand, and they want to participate in this upside with NRG. When Frank Value initiated its position in NRG at $35 in June of 2023, the company had a flat growth rate. Currently, at $155, NRG is guiding at least 14% growth in Adjusted Earnings Per Share for each of the next five years not considering upside surprises from potential deals with AI datacenter buildouts from the hyper-scaler technology companies. It was the right decision to purchase more NRG during the AI factor freakout earlier this year and to also add Vistra to our portfolio amidst the tariff tantrum. Our valuation targets on NRG and Vistra are still materially higher here as most participants (indexers) are apathetic to the fundamentals, which continue to surprise on the upside. NRG and Vistra are far smaller components of the S&P 500 than their fundamentals merit, and these companies will add additional value to shareholders by repurchasing stock at discounted valuations or executing deals like the LS Power acquisition.

BSD Analysis:
NRG appears positioned as a major beneficiary of accelerating U.S. electricity demand driven by data center load growth and grid constraints. The LS Power acquisition expands its generation footprint and signals industry confidence in NRG’s long-term value creation. Strong EPS growth guidance, improving asset mix, and disciplined capital allocation—including buybacks at discounted valuations—support continued rerating potential. Structural demand shifts from AI infrastructure strengthen visibility into multi-year earnings expansion. Risks center on regulatory changes and integration of newly acquired assets, but fundamentals appear materially stronger than the company’s current index weighting suggests.

Pitch Summary:
UK-based gaming software provider reshaped by two major deals: restructuring with Caliplay (now 30.8% equity stake) and €2.3B sale of Snaitech to Flutter. Post-special dividend, the stub consists of B2B operations, Caliplay stake, and smaller assets like Hard Rock Digital. B2B margins are low-teens but improving as loss-making ops are exited; Live Casino is the “crown jewel” with high barriers and US optionality. Caliplay stake alone could justify TEV, as it dominates Mexico’s market. Other upside stems from Hard Rock’s Florida monopoly and call options on Colombian/Brazilian operators. Management’s aggressive comp plan suggests asset monetization is likely. Risks include governance, shareholder blocks, and regulatory pressure.

BSD Analysis:
Playtech’s current valuation underappreciates its portfolio of high-value assets, particularly Caliplay and Live Casino, which could re-rate materially with better utilization and monetization events. B2B restructuring and exits from loss-makers should drive rapid margin improvement, while US Live Casino could double profitability as studios scale. The Caliplay stake is strategic and could IPO or be acquired by Flutter at a premium, offering a major liquidity event. Hard Rock Digital adds hidden upside with Florida exclusivity. Risks are real: management’s compensation structure may skew incentives, Asian shareholder groups could block M&A, and gaming remains a politically exposed industry. Still, the stub offers asymmetric upside for investors comfortable with governance and regulatory risk.

Pitch Summary:
World’s largest industrial gases producer with ~33% share, benefiting from local network dominance, rational competition, and mission-critical services. Revenue split across on-site (25%), merchant (32%), and packaged gases (38%), creating stable cash flows. Historical returns exceed 14% on gross PPE with reinvestment opportunities at >12% IRR. Pricing historically outpaces costs, with inflation and renewals likely to enhance spread going forward. Capital allocation adds ~4–6% EPS growth via disciplined projects, buybacks, and M&A. Management guides to 8–12% EPS CAGR long-term. At ~28x owner earnings, investors can expect ~10–12% IRRs with limited disruption risk.

BSD Analysis:
Linde is a quintessential compounder: global scale, pricing power, and inflation-protected contracts create a resilient moat. The company reinvests a quarter of earnings at double-digit IRRs, while buybacks and dividends provide steady capital return. Although valuation is not cheap, expected IRRs of 10–12% are attractive for a defensive, low-disruption business. Upside comes from stronger industrial production, which offers latent operating leverage. Risks are limited to cyclical downturns or regulatory scrutiny, but competitive discipline minimizes margin pressure. For long-term allocators, LIN is a core compounder worth holding indefinitely.

Pitch Summary:
Clinical-stage biotech developing AAV-based gene therapies for inherited retinal diseases. Lead asset OPGx-LCA5 has shown curative responses in adults and early pediatric data expected 3Q25, with BEST1 following in 1Q26. RMAT designations accelerate regulatory path and both programs could secure valuable Priority Review Vouchers (~$100M+). Backed by strong scientific pedigree (Spark founders) and insider participation in 2025 financing. Cash runway into 2026 plus Viatris royalties/milestones from partnered assets provide non-dilutive funding. Valuation depressed (~$60M mkt cap vs. $300M potential post-BEST1 readout).

BSD Analysis:
Opus is a high-risk/high-reward orphan gene therapy play with near-term binary catalysts. LCA5 pediatric data could validate platform and set up a pivotal trial, while BEST1 expands TAM. The PRV angle provides tangible monetization even before significant sales, derisking returns. Risks include regulatory scrutiny, high manufacturing costs, payer resistance to pricing, and biotech volatility. Still, asymmetric upside exists given Luxturna precedent and insider alignment. For sophisticated investors, small sizing is warranted to capture optionality.

Pitch Summary:
Bonds trade at 78 (YTM ~21%) with 9.5% coupon and partial amortization starting Oct 2026 (25% repaid at par). Company operates in Colombia, Canada, Ecuador; leverage ~2×, targeting <1× by 2027. Liquidity decent with $77M cash + undrawn revolver. Despite FCF sensitivity to oil, amortization + coupon provide downside protection and attractive carry.

BSD Analysis:
Distressed pricing reflects oil volatility, but amortization schedule de-risks principal and strong coupon supports total return. Risks: oil price downturn, weaker credit markets. Relative to peers, notes look cheap with asymmetric payoff.

Pitch Summary:
EQT Corporation is well-positioned to capitalize on the rising demand for natural gas, driven by increased electricity consumption and the digital revolution. The company's strong financial performance, characterized by a significant increase in natural gas sales volume and operating revenue, highlights its ability to leverage favorable market conditions. Despite its high valuation, EQT's robust balance sheet, efficient cost management, and strategic debt reduction efforts underscore its long-term sustainability. The anticipated growth in natural gas demand, coupled with EQT's production capabilities, supports a bullish outlook.

BSD Analysis:
EQT's financial health is underscored by its impressive free cash flow generation, converting approximately 50% of its natural gas and pipeline revenue into free cash in Q1 2025. This financial strength enables the company to sustain dividend payouts and share buybacks, enhancing shareholder value. The company's prudent debt management, with a significant portion of borrowings maturing in over five years, provides a solid foundation for future growth. Market dynamics, such as the expected increase in natural gas prices and electricity consumption, further bolster EQT's growth prospects. Additionally, the expansion of data centers globally is likely to drive further demand for natural gas, positioning EQT advantageously in the energy sector. Despite potential risks from oil price volatility, EQT's strategic focus on natural gas and its operational efficiencies make it a compelling investment opportunity.

Pitch Summary:
SharkNinja has demonstrated robust growth and innovation in the consumer discretionary sector, outperforming many peers since its IPO. Despite tariff-related challenges, the company has shown resilience with strong product lines and impressive sales growth. The stock is currently undervalued compared to the broader market, offering a compelling investment opportunity as it continues to expand its market share and innovate in various product categories.

BSD Analysis:
SharkNinja's ability to maintain a gross margin of 49.3% amidst tariff concerns highlights its operational efficiency and pricing power. The company's forward P/E ratio of 18.7x is attractive, especially against the S&P 500's 22x, suggesting room for valuation expansion. With a diversified supply chain and strategic cost reductions, SharkNinja is well-positioned to mitigate tariff impacts. The company's focus on premium offerings and collaborations with social media influencers enhances brand visibility and consumer engagement. As the macroeconomic environment stabilizes, SharkNinja's innovative product pipeline and strategic market positioning could drive sustained earnings growth, making it a strong candidate for long-term investment portfolios.

Pitch Summary:
Nu Holdings is positioned as a key player in the digital finance sector in Latin America, with a strong focus on financial inclusion and technological innovation. The company has shown impressive growth metrics, including a 40% YoY revenue increase and a significant rise in customer base across its primary markets. Despite a demanding valuation, its robust financial performance, including high net margins and ROE, supports a bullish outlook. The company's strategic expansion into new markets and its commitment to AI-driven solutions further enhance its growth potential.

BSD Analysis:
Nu Holdings' valuation, with a P/E TTM of 30.45x and a P/S TTM of 11.39x, reflects high growth expectations. However, its financial metrics justify this premium, with a 32.91% annualized revenue growth rate and a net income growth rate of nearly 70% per annum. The company's ROE of 28% and net margins of 38% are significantly above industry averages, indicating strong profitability. Nu's strategic expansion into regions like Africa and Asia, coupled with its AI-first approach, positions it well for sustained growth. Despite regulatory and competitive challenges, Nu's ability to innovate and adapt to changing environments is a key strength. The company's robust operating cash flow of over $4B supports its expansion plans, making it a compelling long-term investment in the fintech space.

Pitch Summary:
Kura Sushi USA, Inc. is facing challenges despite its rapid expansion strategy. The company is struggling with weak comparable store sales and thin profitability margins. The stock is currently overvalued, with a market price significantly higher than its estimated fair value. Given the weak immediate earnings outlook and ambitious growth assumptions priced into the stock, the risk-to-reward ratio appears unfavorable.

BSD Analysis:
Kura Sushi's aggressive expansion has led to a rapid increase in restaurant units, but this growth has not translated into improved profitability. The company's operating cash flow is positive, yet it continues to burn cash for new investments, leading to thin GAAP operating losses. The restaurant-level operating margin has declined due to sales deleverage from weaker traffic, compounded by tariff pressures on costs. Despite a strong balance sheet with no interest-bearing debt and substantial cash reserves, the need for equity raises in late 2024 highlights financial strain. The DCF model suggests a fair value of $41.91, significantly below the current stock price, indicating overvaluation. The company's reliance on a high growth rate and operating leverage to justify its valuation seems risky given current performance trends. With a WACC of 10.75% and a high beta of 1.44, the stock's volatility and market risks further underscore the bearish outlook.

Pitch Summary:
Herc Holdings is positioned to benefit from a surge in infrastructure and industrial projects, supported by federal funding and corporate on-shoring. The company is expanding its market share through strategic acquisitions, such as the pending H&E Equipment deal, and is focusing on higher-margin specialty equipment. Despite its high leverage, Herc's strong cash flow and diversified customer base provide resilience against market fluctuations.

BSD Analysis:
Herc Holdings' financials reveal a company with strong revenue growth but significant leverage. The company's debt-to-equity ratio is notably high at approximately 372%, which poses a risk in a rising interest rate environment. However, Herc's strategic focus on large-scale projects and specialty equipment could drive future growth, supported by its robust cash flow generation. The equipment rental industry is expected to grow by 5-7% in 2025, aligning with Herc's growth outlook. While the company's valuation multiples are higher than peers, reflecting market optimism, the execution of its acquisition strategy and the integration of H&E Equipment will be crucial. Investors should monitor the company's ability to manage its debt while capitalizing on infrastructure spending to sustain its premium valuation.

Pitch Summary:
Medifast is poised for a significant turnaround driven by a revitalized coach network and strategic product expansions. The company has seen a reversal in coach sign-up trends, with new sign-ups showing double-digit growth, indicating a potential return to growth by FY26. The introduction of the ASCEND product line, tailored for GLP-1 medication users, is expected to enhance client retention and lifetime value. Despite current market skepticism, Medifast's valuation is attractive, with a forward P/S multiple below its historical average, suggesting substantial upside potential.

BSD Analysis:
Medifast's strategic shift towards leveraging its coach network and digital engagement tools positions it well for a recovery. The company's focus on the ASCEND product line, which addresses the needs of GLP-1 medication users, is a key differentiator in the weight management industry. With a market cap of $154 million, the stock is undervalued relative to its growth prospects, especially given the expected revenue inflection by FY26. The company's forward P/S multiple of 1.3x is conservative compared to its historical median and sector peers, providing a margin of safety. However, risks such as regulatory changes and potential challenges in coach recruitment and retention could impact the growth trajectory. Monitoring coach productivity and digital tool rollouts will be crucial in assessing the company's ability to execute its strategy effectively.